Inovio Pharmaceuticals Inc
INO.O- Latest Trade
- trading higher1.99USD
- Change
- 0.24
- % Change
13.71%Positive
- Day Range
- 1.79 - 2.00
- 52-Week Range
- 1.60 - 10.33
As of May 28 2022. Values delayed up to 15 minutes
- Previous Close
- 1.75
- Open
- 1.84
- Volume
- 10,637,863.00
- 3 Month Average Trading Volume
- 121.26
- Shares Out (Mil)
- 229.04
- Market Cap
- 400.82
- Forward P/E
- -1.48
- Dividend Yield
- -99,999.99
Key Statistics
2.875 mean rating - 8 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 250.09
- Price To Book (Quarterly)
- 1.12
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 4.56
- Long Term Debt/Equity (Quarterly)
- 4.56
- Return On Investment (TTM)
- -65.27
- Return On Equity (TTM)
- -59.28
2021 (millions USD)
About Inovio Pharmaceuticals Inc
Company Information
Inovio Pharmaceuticals, Inc. (INOVIO) is a biotechnology company. The Company is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The Company's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
Address
6769 Mesa Ridge RdSAN DIEGO, CA
92121-2995
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Jacqueline Elizabeth Shea
- President, Chief Executive Officer, Director
- Jay P. Shepard
- Non-Executive Independent Vice Chairman of the Board
- Peter D. Kies
- Chief Financial Officer
- Asli Gevgilili
- Chief Human Resource Officer
- Laurent M. Humeau
- Chief Scientific Officer
- Robert L. Crotty
- General Counsel
- Gene Kim
- Chief Corporate Affairs Officer
- Mark C. Twyman
- Chief Commercial Officer
- David B. Weiner
- Director
- Roger D. Dansey
- Independent Director
- Ann Calby Miller
- Independent Director
- Wendy L. Yarno
- Independent Director
- Lota S. Zoth
- Independent Director
Latest News
- BusinessInovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO
Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell.
- MarketsHewlett Packard, Pfizer, coal stocks
U.S. stock indexes rallied more than 1% on Wednesday as Federal Reserve Chair Jerome Powell signaled the central bank would start raising rates this month, although at a steady pace in the wake of the ongoing Ukraine crisis.
- BusinessInovio lab tests show COVID vaccine weaker against Omicron, trial enrollment paused
Inovio Pharmaceuticals Inc has paused enrollment for an ongoing late-stage study of its lead COVID-19 vaccine candidate after the shot showed significantly lower levels of antibodies against the Omicron variant in lab testing.
- MarketsApple, Macy's, Moderna
The Dow dragged Wall Street's main indexes lower on Friday, with travel, bank and commodity-linked stocks bearing the brunt of a selloff triggered by the discovery of a new and possibly vaccine-resistant coronavirus variant.
- WorldU.S. FDA lifts clinical hold on Inovio's COVID-19 vaccine trial
Inovio Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration (FDA) had lifted a partial clinical hold on late-stage trial of its COVID-19 vaccine within the country.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,850.60 | 0.16%Positive |
| Copper | 776.75 | 0.69%Positive |
| Brent Crude Oil | 119.43 | -- |
| CBOT Soybeans | 1,732.50 | 0.35%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,158.24 | 2.47%Positive |
| Euro STOXX 50 | 3,808.86 | 1.83%Positive |
| FTSE 100 | 7,585.46 | 0.27%Positive |
| Nikkei 225 | 26,781.68 | 0.66%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes